טוען...
Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis
There is a significant unmet need for safe and effective anti‐inflammatory treatment for cystic fibrosis. The aim of this study was to evaluate the safety of acebilustat, a leukotriene A4 hydrolase inhibitor, and its effect on inflammation biomarkers in patients with cystic fibrosis. Seventeen patie...
שמור ב:
| הוצא לאור ב: | Clin Transl Sci |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5351012/ https://ncbi.nlm.nih.gov/pubmed/27806191 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12428 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|